BR112022000854A2 - Conjugados anticorpo - agonista de sting e seu uso em imunoterapia - Google Patents
Conjugados anticorpo - agonista de sting e seu uso em imunoterapiaInfo
- Publication number
- BR112022000854A2 BR112022000854A2 BR112022000854A BR112022000854A BR112022000854A2 BR 112022000854 A2 BR112022000854 A2 BR 112022000854A2 BR 112022000854 A BR112022000854 A BR 112022000854A BR 112022000854 A BR112022000854 A BR 112022000854A BR 112022000854 A2 BR112022000854 A2 BR 112022000854A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- immunotherapy
- sting agonist
- agonist conjugates
- conjugates
- Prior art date
Links
- 229940044665 STING agonist Drugs 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876590P | 2019-07-19 | 2019-07-19 | |
| US202063019212P | 2020-05-01 | 2020-05-01 | |
| PCT/US2020/042815 WO2021016204A1 (en) | 2019-07-19 | 2020-07-20 | Antibody-sting agonist conjugates and their use in immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000854A2 true BR112022000854A2 (pt) | 2022-03-08 |
Family
ID=71995149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000854A BR112022000854A2 (pt) | 2019-07-19 | 2020-07-20 | Conjugados anticorpo - agonista de sting e seu uso em imunoterapia |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11033635B2 (https=) |
| EP (1) | EP3999118A1 (https=) |
| JP (1) | JP7576779B2 (https=) |
| KR (1) | KR20220054794A (https=) |
| CN (2) | CN117838878A (https=) |
| AU (1) | AU2020315802A1 (https=) |
| BR (1) | BR112022000854A2 (https=) |
| CA (1) | CA3147890A1 (https=) |
| IL (1) | IL289866A (https=) |
| MX (1) | MX2022000815A (https=) |
| TW (1) | TWI877186B (https=) |
| WO (1) | WO2021016204A1 (https=) |
| ZA (1) | ZA202201988B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3147890A1 (en) * | 2019-07-19 | 2021-01-28 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
| WO2022225827A1 (en) * | 2021-04-21 | 2022-10-27 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| CA3222082A1 (en) * | 2021-06-25 | 2022-12-29 | Gary Brandt | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof |
| US20240417486A1 (en) * | 2021-10-04 | 2024-12-19 | Bolt Biotherapeutics, Inc. | Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof |
| CN118524854A (zh) * | 2021-12-17 | 2024-08-20 | 北京加科思新药研发有限公司 | 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途 |
| TW202434307A (zh) * | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| CN120813607A (zh) * | 2023-02-28 | 2025-10-17 | 卫材R&D管理有限公司 | 抗psma抗体、缀合物和使用方法 |
| WO2025007108A2 (en) * | 2023-06-30 | 2025-01-02 | Immunogenesis, Inc. | Compositions comprising sting agonists and methods of use for treating glioma |
| CN117343111B (zh) * | 2023-12-04 | 2024-02-06 | 康羽生命科学技术(苏州)有限公司 | 核苷修饰物n2-异丁酰-2'-甲氧基鸟苷的制备方法 |
| CN120204418A (zh) * | 2023-12-27 | 2025-06-27 | 上海迪诺医药科技有限公司 | 环状二核苷酸化合物、其偶联物及应用 |
| WO2026035986A1 (en) | 2024-08-07 | 2026-02-12 | Bighat Biosciences, Inc. | Humanized anti-cdh17 antibodies and use of the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| DK1791565T3 (en) * | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| GB2552041A (en) * | 2015-12-07 | 2018-01-10 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct-agonist conjugates and methods thereof |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| AU2017321609C1 (en) | 2016-08-30 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
| PE20210255A1 (es) * | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| AU2017378782A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| WO2018118665A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| EP3505188A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
| CA3147890A1 (en) | 2019-07-19 | 2021-01-28 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
-
2020
- 2020-07-20 CA CA3147890A patent/CA3147890A1/en active Pending
- 2020-07-20 EP EP20753611.1A patent/EP3999118A1/en active Pending
- 2020-07-20 BR BR112022000854A patent/BR112022000854A2/pt unknown
- 2020-07-20 CN CN202311611339.0A patent/CN117838878A/zh active Pending
- 2020-07-20 CN CN202080064941.5A patent/CN114786729B/zh active Active
- 2020-07-20 WO PCT/US2020/042815 patent/WO2021016204A1/en not_active Ceased
- 2020-07-20 KR KR1020227005267A patent/KR20220054794A/ko active Pending
- 2020-07-20 US US16/933,845 patent/US11033635B2/en active Active
- 2020-07-20 AU AU2020315802A patent/AU2020315802A1/en not_active Abandoned
- 2020-07-20 TW TW109124478A patent/TWI877186B/zh active
- 2020-07-20 MX MX2022000815A patent/MX2022000815A/es unknown
- 2020-07-20 JP JP2022502910A patent/JP7576779B2/ja active Active
-
2021
- 2021-05-11 US US17/317,864 patent/US11213592B2/en active Active
- 2021-12-16 US US17/553,624 patent/US12311030B2/en active Active
-
2022
- 2022-01-16 IL IL289866A patent/IL289866A/en unknown
- 2022-02-16 ZA ZA2022/01988A patent/ZA202201988B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3147890A1 (en) | 2021-01-28 |
| CN117838878A (zh) | 2024-04-09 |
| AU2020315802A1 (en) | 2022-02-24 |
| US20210290774A1 (en) | 2021-09-23 |
| US20220105198A1 (en) | 2022-04-07 |
| TWI877186B (zh) | 2025-03-21 |
| ZA202201988B (en) | 2023-10-25 |
| US20210015941A1 (en) | 2021-01-21 |
| US12311030B2 (en) | 2025-05-27 |
| WO2021016204A1 (en) | 2021-01-28 |
| JP7576779B2 (ja) | 2024-11-01 |
| IL289866A (en) | 2022-03-01 |
| US11213592B2 (en) | 2022-01-04 |
| EP3999118A1 (en) | 2022-05-25 |
| US11033635B2 (en) | 2021-06-15 |
| MX2022000815A (es) | 2022-05-03 |
| TW202116358A (zh) | 2021-05-01 |
| CN114786729B (zh) | 2023-12-19 |
| KR20220054794A (ko) | 2022-05-03 |
| CN114786729A (zh) | 2022-07-22 |
| JP2022541517A (ja) | 2022-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000854A2 (pt) | Conjugados anticorpo - agonista de sting e seu uso em imunoterapia | |
| MX2020013169A (es) | Conjugados de camptotecina. | |
| CL2019000334A1 (es) | Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357) | |
| BR112019022495A2 (pt) | Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação | |
| MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
| CL2022003788A1 (es) | Moléculas de unión contra bcma y usos de las mismas | |
| MX2019008538A (es) | Conjugados de superficie celular y composiciones y métodos celulares relacionados. | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| IL285254A (en) | Compositions containing, methods and uses of antibody-tlr agonist conjugates | |
| CL2019002036A1 (es) | Anticuerpo contra bcma y su uso. | |
| BR112017012344A2 (pt) | anticorpos anti-c10orf54 e usos dos mesmos | |
| BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
| MX2018004531A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| CL2019001745A1 (es) | Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas. | |
| MX2016005689A (es) | Celulas no t efectoras y madre/progenitoras hematopoyeticas modificadas y usos de estas. | |
| ECSP21089206A (es) | Conjugados de anticuerpo y fármaco | |
| CR20160570A (es) | Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| BR112015027322A8 (pt) | Compostos antissenso conjugados e sua utilização | |
| MX2016002643A (es) | Conjugados de penetracion celular y metodos de uso de estos. | |
| CL2018001334A1 (es) | Anticuerpos y conjugados anticuerpo-fármaco anti-5t4. | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| BR112015032200A2 (pt) | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo | |
| BR112015016817A8 (pt) | métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica | |
| MX2015013832A (es) | Composicion de vacuna y metodo de uso. |